Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells.

Stanley LyVivek AnandFouad El-DanaKhoa NguyenYiming CaiShirong CaiHelen Piwnica-WormsDebasish TripathyAysegul A SahinMichael AndreeffVenkata Lokesh Battula

Published in: Journal for immunotherapy of cancer (2021)

Dinutuximab successfully eliminated GD2+ cells and reduced tumor growth in both in vivo models. Our data provide proof-of-concept for the criticality of GD2 in BCSCs and demonstrate the potential of dinutuximab as a novel therapeutic approach for TNBC.

Keyphrases

induced apoptosis
cell cycle arrest
electronic health record
oxidative stress
big data
endoplasmic reticulum stress
cell death
machine learning
signaling pathway
deep learning
artificial intelligence
human health